Results of the cardiovascular outcomes LEADER trial have shown the GLP-1 agonist liraglutide to significantly reduce the risk of major adverse cardiovascular events. The trial, which began in 2010, included 9340 high-risk adults with type 2 diabetes who were randomized to either placebo or liraglutide along with standard treatment. The primary endpoint of LEADER was defined as the composite outcome of the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The superior reduction of major adverse cardiovascular events demonstrated by liraglutide was derived from all three components of the endpoint.
Last year, the SGLT-2 inhibitor empagliflozin was the first glucose-lowering agent to demonstrate cardiovascular risk reduction in a CV outcomes trial. Other CV outcomes trials have shown neutral results with regard to cardiovascular risk reduction or have raised concern about a potentially increased risk for heart failure.
Full data from LEADER are expected to be presented at the American Diabetes Association’s Annual Scientific Sessions in June. For additional commentary on LEADER read more here.
Perspective on these results will also be shared by our expert faculty during “The Shifting Sands of CVD Prevention in Diabetes––A New Outlook for Patient Care,” during The Best of the CMHC Regional Conference Series, in Atlanta on May 7, 2016 and in Chicago on June 18, 2016, and at the 11th Annual CMHC in Boston, October 5-8, 2016.
Medscape. Top-line data show CV benefit for liraglutide in type 2 diabetes.